Vitrase Gains New Molecular Entity Status Due To Lack Of Characterization
This article was originally published in The Pink Sheet Daily
Executive Summary
Ista’s ovine hyaluronidase is given five years of exclusivity, but Amphastar’s recently approved bovine version Amphadase is grandfathered in. FDA cites “inadequate” data to determine whether Vitrase is the same as previously approved hyaluronidase.
You may also be interested in...
FDA “Unable” To Act On Hylenex By User Fee Deadline
Approval of Halozyme Therapeutics’ hyaluronidase product could be bogged down by ongoing legal arguments over Ista’s Vitrase exclusivity.
FDA “Unable” To Act On Hylenex By User Fee Deadline
Approval of Halozyme Therapeutics’ hyaluronidase product could be bogged down by ongoing legal arguments over Ista’s Vitrase exclusivity.
Ista Vitrase Launch Set For Early 2005 With Approval Of Smaller Vial Size
Company plans to differentiate the spreading agent based on preservative-free formulation and 200 unit/mL vial size. Inability to fully characterize hyaluronidase results in Vitrase and Amphadase both having new molecular entity status. Ista is in discussions with FDA about “approvable” letter for vitreous hemorrhage indication.